Amélie Bonnefond PhD Human Genetics

Course and current status

From 2004 to 2007, Amélie Bonnefond studied agronomy, food-processing and management, at Montpellier SupAgro (Montpellier National Superior School of Agronomy, France) where she got a diploma of Agronomist (5-year higher education degree in Agronomy). In parallel, she was graduated in Human Biology and Health at Montpellier II University (France) where she got a Master Degree with a thesis entitled: “MYEOV is a new prognostic factor in multiple myeloma” (in the Inserm unit U847, Institute of Research in Biotherapy, Montpellier, France).

From 2007 to 2010, she prepared a PhD in the CNRS unit UMR8199 (Lille, France) headed by Prof Philippe Froguel, on “the genetics of glucose control”, under the guidance of Dr Martine Vaxillaire.

In 2011, Amélie Bonnefond was a postdoctoral researcher in the Inserm unit #1122 (Lorraine University, Nancy, France) headed by Dr Sophie Visvikis-Siest. She worked on the genetics of cardiovascular diseases and associated quantitative traits, in the post-GWAS era.

In 2012, Amélie Bonnefond came back to Philippe Froguel’s lab as a postdoctoral fellow. Since then, she has been head of the next-generation sequencing development and optimization group.

In 2012, she was also a visiting postdoctoral researcher in the Inserm unit U695 (Paris, France), headed by Prof Michel Marre, where she studied the genetics of micro- and macrovascular complications (and related traits) of type 2 diabetes.

In October 2014, she has been appointed Senior Research Associate by the Inserm (the French National Institute of Health and Medical Research).

Her own research is now focused on the contribution of rare genetic events to the risk of type 2 diabetes and obesity.

Scientific summary

So far, the scientific career of Amélie Bonnefond has been focused on the dissection of the genetic etiologies of type 2 diabetes (T2D), obesity and cardiovascular diseases in order to elucidate their physiology towards a better stratification of the patients and a putative identification of new drugs towards more personalized medicine.

Her achievements and expertise have been:

I/ Genome-wide association studies (GWAS) or targeted association studies of quantitative traits to identify novel loci associated with risk of T2D/obesity/cardiovascular disease;

II/ Genetic and functional evaluations of the contribution of rare variants in genes of interest (identified via GWAS, animal or familial studies), to either monogenic diabetes/obesity or to common T2D/obesity risk;

III/ Detection of large chromosomal clonal mosaic events (CMEs) through DNA arrays and association with risk of T2D and vascular complications;

IV/ Next-generation sequencing and identification of new mutations or genes involved in monogenic diabetes

Image d’exemple